Vivoryon Therapeutics N.V.
Stock Forecast, Prediction & Price Target

Vivoryon Therapeutics N.V. Financial Estimates

Vivoryon Therapeutics N.V. Revenue Estimates

Vivoryon Therapeutics N.V. EBITDA Estimates

Vivoryon Therapeutics N.V. Earnings per Share Estimates

Passed Analyst forecast
Metric 12/31/2021 12/31/2022 12/31/2023 12/31/2025 12/31/2026 12/31/2027 12/31/2028
Revenue
 
% change YoY
€10.76M
 
N/A
€0
 
-100%
€-3.62M
 
0%
Avg: €-2.03M
Low: €-2.03M
High: €-2.03M
avg. 43.75%
Avg: €-1.52M
Low: €-1.52M
High: €-1.52M
avg. 25.00%
Avg: €339.7M
Low: €339.7M
High: €339.7M
avg. 22343.51%
Avg: €-859.04K
Low: €-859.04K
High: €-859.04K
avg. -100.25%
Net Income
 
% change YoY
€-12.65M
 
N/A
€-28.15M
 
-122.48%
€-28.34M
 
-0.66%
Avg: €-14.76M
Low: €-14.76M
High: €-14.76M
avg. 47.89%
Avg: €-14.89M
Low: €-14.89M
High: €-14.89M
avg. -0.85%
Avg: €-14.13M
Low: €-14.13M
High: €-14.13M
avg. 5.08%
Avg: €-15.14M
Low: €-15.14M
High: €-15.14M
avg. -7.14%
EBITDA
 
% change YoY
€-12.64M
 
N/A
€-28.97M
 
-129.18%
€-28.35M
 
2.13%
Avg: €-1.22M
Low: €-1.22M
High: €-1.22M
avg. 95.69%
Avg: €-916.31K
Low: €-916.31K
High: €-916.31K
avg. 25.00%
Avg: €203.82M
Low: €203.82M
High: €203.82M
avg. 22343.51%
Avg: €-515.42K
Low: €-515.42K
High: €-515.42K
avg. -100.25%
EPS
 
% change YoY
-$0.63
 
N/A
-$1.28
 
-103.17%
-$1.12
 
12.49%
Avg: -$0.59
Low: -$0.59
High: -$0.59
avg. 47.76%
Avg: -$0.59
Low: -$0.59
High: -$0.59
avg. -0.85%
Avg: -$0.56
Low: -$0.56
High: -$0.56
avg. 5.08%
Avg: -$0.6
Low: -$0.6
High: -$0.6
avg. -7.14%
Operating Expenses
 
% change YoY
€21.83M
 
N/A
€28.97M
 
32.67%
€25.74M
 
-11.14%
Avg: €-433.61K
Low: €-433.61K
High: €-433.61K
avg. -101.68%
Avg: €-325.21K
Low: €-325.21K
High: €-325.21K
avg. 25%
Avg: €72.33M
Low: €72.33M
High: €72.33M
avg. 22343.51%
Avg: €-182.93K
Low: €-182.93K
High: €-182.93K
avg. -100.25%

FAQ

What is Vivoryon Therapeutics N.V. stock earnings growth forecast?

Wall Street analysts estimate the annual average earnings growth rate of 11.24% in 2025-2028.

We have gathered data from N/A analysts. Their low estimate is -14.76M, average is -14.76M and high is -14.76M.

What is Vivoryon Therapeutics N.V. stock revenue growth forecast?

Wall Street analysts forecast annual average revenue growth of 5578.00% in 2025-2028.

We have gathered data from N/A analysts. Their low revenue estimate is €-2.03M, average is €-2.03M and high is €-2.03M.

What is Vivoryon Therapeutics N.V. stock earnings per share growth forecast?

Wall Street analysts forecast annual average earnings growth of 11.21% in 2025-2028.

We have gathered data from N/A analysts. Their low earnings per share estimate is -$0.59, average is -$0.59 and high is €-0.58.